<p>Capricor Therapeutics（纳斯达克代码：CAPR - 获取免费报告）于周四发布了季度财报。这家生物技术公司报告的每股收益为（$0.62），低于市场共识预期的（$0.51），差距为（$0.11），FiscalAI 报道。</p>
<p>获取 <strong>Capricor Therapeutics</strong> 的提醒：</p>
<h2>Capricor Therapeutics 股票下跌 0.4%</h2>
<ul>
<li>Capricor Therapeutics 股价上涨超过 100%，可能会进一步上涨</li>
</ul>
<p>周四中午交易时，CAPR 股票下跌 $0.15，达到 $33.42。该公司共交易了 1,224,128 股股票，而其平均交易量为 1,328,225 股。该公司的市值为 18.5 亿美元，市盈率为 -18.57，贝塔值为 0.37。Capricor Therapeutics 的 12 个月最低价为 $4.30，最高价为 $40.37。该公司的 50 日移动平均价格为 $25.57，200 日移动平均价格为 $16.24。</p>
<h2>机构投资者对 Capricor Therapeutics 的看法</h2>
<p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。加拿大皇家银行在第四季度增持了 Capricor Therapeutics 的股份，增幅为 12.4%。加拿大皇家银行目前拥有 5,040 股该生物技术公司的股票，价值 146,000 美元，此前在上个季度增持了 557 股。Orion Portfolio Solutions LLC 在第四季度购买了 Capricor Therapeutics 的新股份，价值约 239,000 美元。纽约州共同退休基金在第四季度增持了 Capricor Therapeutics 的股份，增幅为 124.1%。纽约州共同退休基金目前拥有 13,000 股该生物技术公司的股票，价值 375,000 美元，此前在上个季度增持了 7,200 股。Voleon Capital Management LP 在第三季度购买了 Capricor Therapeutics 的新股份，价值约 311,000 美元。最后，Moneta Group Investment Advisors LLC 在第三季度增持了 Capricor Therapeutics 的股份，增幅为 25.5%。Moneta Group Investment Advisors LLC 目前拥有 34,454 股该生物技术公司的股票，价值 248,000 美元，此前在上个季度增持了 7,000 股。机构投资者持有该公司 21.68% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票分析师最近对 CAPR 股票发表了看法。Oppenheimer 将 Capricor Therapeutics 的目标价格从 $22.00 上调至 $54.00，并在 12 月 8 日的研究报告中给予该公司 “跑赢大盘” 的评级。Alliance Global Partners 在 12 月 3 日的研究报告中重申了对 Capricor Therapeutics 的 “买入” 评级。Maxim Group 在 12 月 4 日的研究报告中将 Capricor Therapeutics 的目标价格从 $25.00 上调至 $50.00，并给予该股票 “买入” 评级。Wall Street Zen 在 1 月 11 日的研究报告中将 Capricor Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，瑞银集团在 12 月 15 日的研究报告中设定了 Capricor Therapeutics 的目标价格为 $50.00。九位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价格为 $40.82。</p>
<p><strong>阅读我们对 Capricor Therapeutics 的最新分析</strong></p>
<h2>更多 Capricor Therapeutics 新闻</h2>
<p>以下是本周影响 Capricor Therapeutics 的主要新闻：</p>
<ul>
<li>积极情绪：FDA 恢复对 deramiocel 的审查并解除之前的暂停——该机构已重新开启对 deramiocel 的 BLA 审查，这是一个重要的监管催化剂，增加了最终批准的可能性，并设定了正式的决策时间表。阅读更多。</li>
<li>积极情绪：最新的 3 期 HOPE-3 数据显示临床上有意义的功能益处——在 2026 年 MDA 会议上展示的额外分析增强了该疗法在 DMD 中的疗效故事，支持了批准的可能性和长期商业潜力。阅读更多。</li>
<li>积极情绪：临床信号扩展到心脏终点——HOPE-3 的报道显示关键心脏功能指标的改善，这是 DMD 患者的重要商业和安全考虑。阅读更多。</li>
<li>积极情绪：分析师支持——HC Wainwright 重申了 “买入” 评级，这可以帮助情绪和零售/机构的兴趣，随着监管透明度的提高。阅读更多。</li>
<li>中性情绪：即将发布的财报和短期催化剂——Capricor 预计很快将发布季度业绩；财报和管理层评论可能会影响短期走势。阅读更多。</li>
<li>中性情绪：空头头寸数据混乱——最近的报告显示异常/零空头头寸数据，且几乎没有覆盖天数；对挤压动态或卖压的影响不明确。（数据摘要）</li>
<li>消极情绪：监管风险依然存在——FDA 之前发出了完整回应信；审查的恢复并不保证批准，且该机构之前的异议强调了执行风险和二元监管结果。阅读更多。</li>
</ul>
<h2>关于 Capricor Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Capricor Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于开发用于心血管和罕见疾病的细胞和外泌体基础的治疗方案。公司总部位于加利福尼亚州比佛利山庄，利用专有的心脏球体衍生细胞（CDC）技术来解决以炎症、纤维化和组织退化为特征的疾病。自成立以来，Capricor 已通过多项临床试验推进其主要候选药物，并建立了涵盖细胞治疗和细胞外囊泡（外泌体）平台的产品管线。</p>
<p>该公司的主要产品候选药物 CAP-1002 由异体 CDC 组成，正在评估用于杜氏肌营养不良症（DMD）和与 COVID-19 相关的心脏损伤等适应症。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Capricor Therapeutics</li>
<li>用这四个简单步骤让你的银行账户 “防联储”</li>
<li>华尔街害怕的黄金图表……</li>
<li>免费：可能改变你生活的加密峰会</li>
<li>历史上最大的首次公开募股即将到来</li>
<li>在 2026 年 5 月 15 日之前购买这只黄金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Capricor Therapeutics 吗？</h2>
<p>在考虑 Capricor Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Capricor Therapeutics 并不在名单上。</p>
<p>虽然 Capricor Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

<p>Capricor Therapeutics（纳斯达克代码：CAPR）报告的季度每股收益为（$0.62），低于预期$0.11。股价下跌 0.4%，至$33.42，市值为 18.5 亿美元。分析师的评级不一，普遍目标价为$40.82。机构投资者持有 21.68% 的股份。近期的积极进展包括 FDA 恢复对 deramiocel 的审查以及有希望的三期数据。然而，在之前收到 FDA 的完整回复信后，监管风险依然存在</p>

<p>Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11), FiscalAI reports.</p>
<div class="lb-trans"><p>Capricor Therapeutics（纳斯达克代码：CAPR - 获取免费报告）于周四发布了季度财报。这家生物技术公司报告的每股收益为（$0.62），低于市场共识预期的（$0.51），差距为（$0.11），FiscalAI 报道。</p>
</div><p>Get <strong>Capricor Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Capricor Therapeutics</strong> 的提醒：</p>
</div><h2>Capricor Therapeutics Stock Down 0.4%</h2>
<div class="lb-trans"><h2>Capricor Therapeutics 股票下跌 0.4%</h2>
</div><ul>
<li>Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>Capricor Therapeutics 股价上涨超过 100%，可能会进一步上涨</li>
</ul>
</div><p>Shares of CAPR stock traded down $0.15 during mid-day trading on Thursday, reaching $33.42. 1,224,128 shares of the company's stock traded hands, compared to its average volume of 1,328,225. The company has a market cap of $1.85 billion, a P/E ratio of -18.57 and a beta of 0.37. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The company's 50-day moving average price is $25.57 and its 200-day moving average price is $16.24.</p>
<div class="lb-trans"><p>周四中午交易时，CAPR 股票下跌 $0.15，达到 $33.42。该公司共交易了 1,224,128 股股票，而其平均交易量为 1,328,225 股。该公司的市值为 18.5 亿美元，市盈率为 -18.57，贝塔值为 0.37。Capricor Therapeutics 的 12 个月最低价为 $4.30，最高价为 $40.37。该公司的 50 日移动平均价格为 $25.57，200 日移动平均价格为 $16.24。</p>
</div><h2>Institutional Investors Weigh In On Capricor Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Capricor Therapeutics 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company's stock valued at $146,000 after acquiring an additional 557 shares during the last quarter. Orion Porfolio Solutions LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter valued at about $239,000. New York State Common Retirement Fund grew its position in shares of Capricor Therapeutics by 124.1% during the fourth quarter. New York State Common Retirement Fund now owns 13,000 shares of the biotechnology company's stock valued at $375,000 after purchasing an additional 7,200 shares in the last quarter. Voleon Capital Management LP purchased a new position in shares of Capricor Therapeutics during the third quarter valued at about $311,000. Finally, Moneta Group Investment Advisors LLC increased its holdings in shares of Capricor Therapeutics by 25.5% in the third quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company's stock worth $248,000 after purchasing an additional 7,000 shares during the last quarter. Institutional investors own 21.68% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。加拿大皇家银行在第四季度增持了 Capricor Therapeutics 的股份，增幅为 12.4%。加拿大皇家银行目前拥有 5,040 股该生物技术公司的股票，价值 146,000 美元，此前在上个季度增持了 557 股。Orion Portfolio Solutions LLC 在第四季度购买了 Capricor Therapeutics 的新股份，价值约 239,000 美元。纽约州共同退休基金在第四季度增持了 Capricor Therapeutics 的股份，增幅为 124.1%。纽约州共同退休基金目前拥有 13,000 股该生物技术公司的股票，价值 375,000 美元，此前在上个季度增持了 7,200 股。Voleon Capital Management LP 在第三季度购买了 Capricor Therapeutics 的新股份，价值约 311,000 美元。最后，Moneta Group Investment Advisors LLC 在第三季度增持了 Capricor Therapeutics 的股份，增幅为 25.5%。Moneta Group Investment Advisors LLC 目前拥有 34,454 股该生物技术公司的股票，价值 248,000 美元，此前在上个季度增持了 7,000 股。机构投资者持有该公司 21.68% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities analysts recently weighed in on CAPR shares. Oppenheimer increased their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 8th. Alliance Global Partners reiterated a &#34;buy&#34; rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Maxim Group increased their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, December 4th. Wall Street Zen lowered Capricor Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Sunday, January 11th. Finally, UBS Group set a $50.00 price objective on shares of Capricor Therapeutics in a research report on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $40.82.</p>
<div class="lb-trans"><p>几位股票分析师最近对 CAPR 股票发表了看法。Oppenheimer 将 Capricor Therapeutics 的目标价格从 $22.00 上调至 $54.00，并在 12 月 8 日的研究报告中给予该公司 “跑赢大盘” 的评级。Alliance Global Partners 在 12 月 3 日的研究报告中重申了对 Capricor Therapeutics 的 “买入” 评级。Maxim Group 在 12 月 4 日的研究报告中将 Capricor Therapeutics 的目标价格从 $25.00 上调至 $50.00，并给予该股票 “买入” 评级。Wall Street Zen 在 1 月 11 日的研究报告中将 Capricor Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，瑞银集团在 12 月 15 日的研究报告中设定了 Capricor Therapeutics 的目标价格为 $50.00。九位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价格为 $40.82。</p>
</div><p><strong>Read Our Latest Analysis on Capricor Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Capricor Therapeutics 的最新分析</strong></p>
</div><h2>More Capricor Therapeutics News</h2>
<div class="lb-trans"><h2>更多 Capricor Therapeutics 新闻</h2>
</div><p>Here are the key news stories impacting Capricor Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Capricor Therapeutics 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: FDA resumes review of deramiocel and lifts prior hold — the agency has reopened the BLA review for deramiocel, a major regulatory catalyst that increases the probability of eventual approval and sets a formal decision timeline. Read More.</li>
<li>Positive Sentiment: Late-breaking Phase 3 HOPE-3 data show clinically meaningful functional benefits — additional analyses presented at the 2026 MDA conference strengthen the therapy’s efficacy story in DMD, which supports both approval probability and long-term commercial potential. Read More.</li>
<li>Positive Sentiment: Clinical signals extend to cardiac endpoints — coverage and reporting of HOPE-3 show improvements in key heart-function measures, an important commercial and safety consideration for DMD patients. Read More.</li>
<li>Positive Sentiment: Analyst support — HC Wainwright reiterated a Buy, which can help sentiment and retail/institutional interest as regulatory clarity improves. Read More.</li>
<li>Neutral Sentiment: Upcoming earnings and near-term catalysts — Capricor is projected to post quarterly results soon; earnings and management commentary can influence the short-term move. Read More.</li>
<li>Neutral Sentiment: Short-interest data are muddled — recent reports show anomalous/zero short-interest figures and effectively no days-to-cover; unclear impact on squeeze dynamics or selling pressure. (Data summary)</li>
<li>Negative Sentiment: Regulatory risk remains — the FDA previously issued a Complete Response Letter; resumption of review does not guarantee approval and the agency’s prior objections underscore execution risk and binary regulatory outcomes. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：FDA 恢复对 deramiocel 的审查并解除之前的暂停——该机构已重新开启对 deramiocel 的 BLA 审查，这是一个重要的监管催化剂，增加了最终批准的可能性，并设定了正式的决策时间表。阅读更多。</li>
<li>积极情绪：最新的 3 期 HOPE-3 数据显示临床上有意义的功能益处——在 2026 年 MDA 会议上展示的额外分析增强了该疗法在 DMD 中的疗效故事，支持了批准的可能性和长期商业潜力。阅读更多。</li>
<li>积极情绪：临床信号扩展到心脏终点——HOPE-3 的报道显示关键心脏功能指标的改善，这是 DMD 患者的重要商业和安全考虑。阅读更多。</li>
<li>积极情绪：分析师支持——HC Wainwright 重申了 “买入” 评级，这可以帮助情绪和零售/机构的兴趣，随着监管透明度的提高。阅读更多。</li>
<li>中性情绪：即将发布的财报和短期催化剂——Capricor 预计很快将发布季度业绩；财报和管理层评论可能会影响短期走势。阅读更多。</li>
<li>中性情绪：空头头寸数据混乱——最近的报告显示异常/零空头头寸数据，且几乎没有覆盖天数；对挤压动态或卖压的影响不明确。（数据摘要）</li>
<li>消极情绪：监管风险依然存在——FDA 之前发出了完整回应信；审查的恢复并不保证批准，且该机构之前的异议强调了执行风险和二元监管结果。阅读更多。</li>
</ul>
</div><h2>About Capricor Therapeutics</h2>
<div class="lb-trans"><h2>关于 Capricor Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.</p>
<div class="lb-trans"><p>Capricor Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于开发用于心血管和罕见疾病的细胞和外泌体基础的治疗方案。公司总部位于加利福尼亚州比佛利山庄，利用专有的心脏球体衍生细胞（CDC）技术来解决以炎症、纤维化和组织退化为特征的疾病。自成立以来，Capricor 已通过多项临床试验推进其主要候选药物，并建立了涵盖细胞治疗和细胞外囊泡（外泌体）平台的产品管线。</p>
</div><p>The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 CAP-1002 由异体 CDC 组成，正在评估用于杜氏肌营养不良症（DMD）和与 COVID-19 相关的心脏损伤等适应症。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Capricor Therapeutics</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>The largest IPO in history is coming</li>
<li>Buy this Gold Stock Before May 15th, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Capricor Therapeutics</li>
<li>用这四个简单步骤让你的银行账户 “防联储”</li>
<li>华尔街害怕的黄金图表……</li>
<li>免费：可能改变你生活的加密峰会</li>
<li>历史上最大的首次公开募股即将到来</li>
<li>在 2026 年 5 月 15 日之前购买这只黄金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CAPR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Capricor Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Capricor Therapeutics 吗？</h2>
</div><p>Before you consider Capricor Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Capricor Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Capricor Therapeutics 并不在名单上。</p>
</div><p>While Capricor Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Capricor Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Capricor Therapeutics (NASDAQ:CAPR) Posts Earnings Results, Misses Expectations By $0.11 EPS

Market Beat

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

美国制药 ETF - iShares

医疗业 ETF - Vanguard

标普生物技术 3 倍做多 - Direxion

Invesco Nasdaq Biotechnology ETF

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

标普生物技术 3 倍做空 - Direxion

Capricor治疗

纳斯达克生物科技指数 ETF - iShares Nasdaq

Capricor 治疗公司（纳斯达克股票代码：CAPR）发布了财报，收益每股比预期低 0.11 美元